Expression of AP-2α, AP-2γ and ESDN in primary melanomas: Correlation with histopathological features and potential prognostic value

Journal of Dermatological Science

Volumn 68, Issue 3, 2012, Pages 202-204

  Osella Abate, Simona ^a   Novelli, Mauro ^a   Quaglino, Pietro ^a   Orso, Francesca ^a   Ubezio, Benedetta ^a   Tomasini, Carlo ^b   Berardengo, Ester ^b   Bernengo, Maria Grazia ^a   Taverna, Daniela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

AP 2alpha; AP 2gamma; DFS; ESDN; Melanoma

Indexed keywords

ENDOTHELIAL AND SMOOTH MUSCLE CELL DERIVED NEUROPILIN LIKE MOLECULE; ONCOPROTEIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR AP 2 GAMMA; UNCLASSIFIED DRUG;

CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LETTER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84868518856     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.09.008     Document Type: Letter

References (10)

1. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206.
2. Karjalainen J.M., Kellokoski J.K., Mannermaa A.J., Kujala H.E., Moisio K.I., Mitchell P.J., et al. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma. Br J Cancer 2000, 82(12):2015-2021.
3. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001, 14(2):78-85.
4. Orso F., Penna E., Cimino D., Astanina E., Maione F., Valdembri D., et al. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J 2008, 22(8):2702-2714.
5. Orso F., Corà D., Ubezio B., Provero P., Caselle M., Taverna D. Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes. BMC Genomics 2010, 11:355.
6. Penna E., Orso F., Cimino D., Tenaglia E., Lembo A., Quaglino E., et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011, 30(10):1990-2007.
7. Nagai H., Sugito N., Matsubara H., Tatematsu Y., Hida T., Sekido Y., et al. CLCP1 interacts with semaphorin 4B and regulates motility of lung cancer cells. Oncogene 2007, 26(27):4025-4031.
8. Ropponen K.M., Kellokoski J.K., Pirinen R.T., Moisio K.I., Eskelinen M.J., Alhava E.M., et al. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001, 54:533-538.
9. Pellikainen J., Kataja V., Ropponen K., Kellokoski J., Pietiläinen T., Böhm J., et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res 2002, 8:3487-3495.
10. Kim M., Lee K.T., Jang H.R., Kim J.H., Noh S.M., Song K.S., et al. Epigenetic down-regulation and suppressive role of DCBLD2 in gastric cancer cell proliferation and invasion. Mol Cancer Res 2008, 6:222-230.